Beijing Konruns Pharmaceutical Co., Ltd.
13
8
8
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 50/100
7.7%
1 terminated/withdrawn out of 13 trials
75.0%
-11.5% vs industry average
15%
2 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
Role: lead
A Study of KC1086 in Patients With Advanced Solid Tumors
Role: lead
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
Role: lead
A Study of KC1036 in Patients with Advanced Thymic Tumors
Role: lead
A Study of KC1036 in Patients with Advanced Solid Tumors
Role: lead
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
Role: lead
A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease
Role: lead
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
Role: lead
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Role: lead
A Food Effect Study of KC1036 in Healthy Subjects
Role: lead
The Effect of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease
Role: lead
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Role: lead
Kanitinib in Treating Patients With Advanced Solid Tumors
Role: lead
All 13 trials loaded